Cytokinetics (CYTK)
(Delayed Data from NSDQ)
$65.27 USD
+0.93 (1.45%)
Updated May 3, 2024 04:00 PM ET
After-Market: $65.26 -0.01 (-0.02%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum F VGM
Average Brokerage Rating
Current ABR | 1.44 |
ABR (Last week) | 1.44 |
# of Recs in ABR | 18 |
Average Target Price | $92.13 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 78 of 252 |
Current Quarter EPS Est: | -1.16 |
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 13 | 13 | 13 | 13 | 12 |
Buy | 2 | 2 | 2 | 2 | 2 |
Hold | 3 | 3 | 3 | 3 | 3 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.44 | 1.44 | 1.44 | 1.44 | 1.47 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
4/9/2024 | Raymond James | Sean Mccutcheon | Moderate Buy | Moderate Buy |
4/9/2024 | Needham & Company | Serge Belanger | Moderate Buy | Moderate Buy |
4/8/2024 | Truist Securities | Srikripa Devarakonda | Strong Buy | Strong Buy |
3/6/2024 | Mizuho SecuritiesUSA | Salim Syed | Strong Buy | Strong Buy |
2/29/2024 | Cantor Fitzgerald & Co | Charles C Duncan | Strong Buy | Strong Buy |
2/28/2024 | Piper Sandler | Yasmeen Rahimi | Strong Buy | Strong Buy |
2/28/2024 | H.C. Wainwright & Co. | Joseph Pantginis | Strong Buy | Strong Buy |
2/16/2024 | JMP Securities | Jason N Butler | Strong Buy | Strong Buy |
11/7/2023 | B. Riley Securities | Mayank Mamtani | Strong Buy | Strong Buy |
8/15/2023 | SVB Securities | Roanna Ruiz | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.